Recruiting Numbers
emovis is not only known for its high recruiting numbers. It is also recognized for maintaining and/or exceeding the forecasted study participants recruiting prospects. The reason: emovis demonstrates high-level expertise and is open to innovation when recruiting patients and the Executive Management typically estimates the number of recruits in a conservative manner. A rule of fairness at emovis: Up to now, numerous sponsors were surprised and quite happy.
Search our past trials and recruitment numbers
| Start | Indication | Sponsor | Time period | Recruited | Trial Identifier |
|---|---|---|---|---|---|
| 2006 | Restless Legs Syndrome | Boehringer Ingelheim Pharma GmbH & Co. KG | 7 months | 21 | EudraCT-2005-006128-13 |
| 2009 | Contraception | Bayer Health Care AG | 9 months | 153 | EudraCT-2009-010599-45 |
| 2009 | Depression | Steigerwald Arzneimittelwerk GmbH | 8 months | 95 | EudraCT-2008-001417-26 |
| 2006 | Irritable Bowel Syndrome | GlaxoSmithKline PLC | 3 months | 28 | n.d. |
| 2006 | Depression | AstraZeneca PLC | 4 months | 13 | EudraCT-2005-003745-14 |
| 2006 | Generalized Anxiety Disorder | AstraZeneca PLC | 9 months | 7 | EudraCT-2005-005055-18 |
| 2006 | Restless Legs Syndrome | Axxonis Pharma AG | 10 months | 26 | EudraCT-2004-001589-42 |
| 2012 | Depression | Institut de Recherches Internationales Servier | n.d. | 24 | EudraCT-2010-024191-25 |
| 2006 | Insomnia | SANOFI-SYNTHELABO RECHERCHE | 18 months | 31 | EudraCT-2005-003082-16 |
| 2006 | Restless Legs Syndrome | UCB (Schwarz Pharma) | 6 months | 21 | EudraCT-2005-000428-18 |
| 2006 | Restless Legs Syndrome | UCB (Schwarz Pharma) | 2 months | 11 | EudraCT-2005-0022611-25 |
| 2006 | Depression | Sanofi-Aventis Recherche & Développement | 4 months | 42 | EudraCT-2004-002327-41 |
| 2004 | Alzheimer's disease | Sanofi | n.d. | 4 | GDCT0030961 |
| 2006 | Depression | Institut de Recherches Internationales Servier | 3 months | 46 | EudraCT-2004-004009-10 |
| 2004 | Restless Legs Syndrome | UCB (Schwarz Pharma), Imerem GmbH | 6 months | 20 | n.d. |
| 2006 | Depression | GlaxoSmithKline PLC | 3 months | 21 | EudraCT-2006-001877-13 |
| 2004 | Diabetic Neuropathy | UCB (Schwarz Pharma) | n.d. | 13 | n.d. |
| 2005 | Panic Disorder | Elbion AG | 1 month | 12 | EudraCT-2005-005708-17 |
| 2003 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | n.d. | 4 | n.d. |
| 2005 | Bronchitis | Bionorica SE | 2 weeks | 3 | EudraCT-2005-003249-15 |
| 2005 | Premenstrual Syndrome | Pfizer Inc. | 8 months | 3 | EudraCT-2004-005173-27 |
| 2019 | Vaccine Influenza | Sanofi Pasteur SA | 1 month | 99 | EudraCT-2019-000655-14 |
| 2005 | Depression | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 7 months | 9 | EudraCT-2004-000167-95 |
| 2005 | Generalized Anxiety Disorder | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 8 months | 17 | EudraCT-2004-002626-22 |
| 2021 | Diabetic Neuropathy | Bayer AG | 4 months | 8 | EudraCT-2020-002066-14 |
| 2005 | Irritable Bowel Syndrome | Astellas Pharma Inc., Yamanouchi Europe B.V. | 2 months | 12 | EudraCT-2004-003880-61 |
| 2019 | Clostridium difficile | Pfizer Inc. | 18 months | 20 | EudraCT-2016-003866-14 |
| 2005 | Depression | GlaxoSmithKline PLC | 2 months | 1 | EudraCT-2004-003803-19 |
| 2016 | Vaccine Herpes Zoster | GlaxoSmithKline PLC | 4 months | 11 | EudraCT-2015-001778-17 |
| 2004 | Generalized Anxiety Disorder | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 10 months | 14 | n.d. |
| 2004 | Social Phobia | GlaxoSmithKline PLC | 5 months | 35 | EudraCT-2004-000848-24 |
| 2021 | COVID-19 | Heidelberg ImmunoTherapeutics GmbH | active | 35 | n.d. |
| 2004 | Irritable Bowel Syndrome | GlaxoSmithKline PLC | 5 months | 49 | EudraCT-2004-000848-24 |
| 2021 | Endometriosis | Bayer AG | 5 months | 4 | EudraCT-2020-003131-16 |
| 2017 | Alzheimer's disease | Biogen Idec Research Limited | 18 months | 55 | EudraCT-2015-000967-15 |
| 2004 | Depression | GlaxoSmithKline PLC | 8 months | 31 | GDCT0259903 |
| 2021 | Vaccine Influenza | Seqirus UK Limited | 3 weeks | 61 | EudraCT-2021-001721-40 |
| 2016 | Irritable Bowel Syndrome | Laves-Arzneimittel GmbH | 4 months | 11 | EudraCT-2011-001743-78 |
| 2004 | Depression | Pfizer Inc. | 3 months | 27 | EudraCT-2004-000562-13 |
| 2016 | Irritable Bowel Syndrome | SymbioPharm GmbH | 5 months | 33 | EudraCT-2012-002741-38 |
| 2004 | Alzheimer's disease | GlaxoSmithKline PLC | 8 months | 2 | EudraCT-2004-000985-12 |
| 2016 | COPD | AstraZeneca PLC | 3 months | 31 | EudraCT-2015-005444-33 |
| 2016 | Contraception | Daiichi Sankyo Deutschland GmbH, Estetra SPRL | 5 months | 21 | EudraCT-2013-005164-26 |
| 2004 | Restless Legs Syndrome | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 months | 49 | GDCT0062955 |
| 2016 | Alzheimer's disease | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 months | 16 | EudraCT-2013-005031-24 |
| 2016 | Alzheimer's disease | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 months | 1 | EudraCT-2013-005040-28 |
| 2010 | Migraine | Merck Sharp & Dohme LLC | 3 months | 27 | EudraCT-2010-019288-13 |
| 2016 | Pain | ESPERION Therapeutics Inc., Boehringer Ingelheim Pharma GmbH & Co. KG | 7 months | 80 | EUdraCT-2015-000404-25 |
| 2003 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | 14 months | 58 | n.d. |
| 2015 | Diabetes Mellitus Type II | AstraZeneca PLC | 4 months | 9 | EudraCT-2015-002376-24 |
| 2003 | Alzheimer's disease | Sanofi-Synthelabo | 34 months | 15 | n.d. |
| 2016 | Hyperlipidemia | ESPERION Therapeutics Inc. | 6 months | 12 | EudraCT-2015-004136-36 |
| 2003 | Depression | H. Lundbeck A/S | 7 months | 21 | n.d. |
| 2021 | Low Back Pain | Vertanical GmbH | active | 16 | EudraCT-2020-000107-36 |
| 2016 | Gastrointestinal Reflux Disease (GERD) | Reckitt Benckiser Healthcare (UK) Limited | 5 months | 47 | EudraCT-2014-005261-69 |
| 2003 | Restless Legs Syndrome | UCB (Schwarz Pharma) | 6 weeks | 32 | GDCT0063543 |
| 2021 | Healthy Subjects | Roche Diagnostics | 4 weeks | 175 | n.d. |
| 2016 | Asthma | AstraZeneca PLC | 1 month | 10 | EudraCT- 2004-004042-41 |
| 2022 | Allergy (Cat Hair) | Regeneron Pharmaceuticals Inc. | active | 5 | EudraCT-2021-002089-42 |
| 2016 | Osteoarthritis | PBB Entrepreneur Ltd. | 4 months | 56 | GDCT0269718 |
| 2004 | Alzheimer's disease | Johnson & Johnson, Janssen-Cilag | 4 months | 5 | n.d. |
| 2021 | Vaccine RSV | Janssen Vaccines & Prevention B.V. | 2,5 months | 3 | EudraCT-2021-001909-77 |
| 2016 | Allergy (Grass pollen) | ALLERGOPHARMA GmbH & Co. KG, Merck KGaA | 2 months | 33 | EudraCT- 2015-002409-13 |
| 2003 | Addiction (Nicotine) | GlaxoSmithKline PLC | 4 days | 101 | n.d. |
| 2016 | Depression | Janssen Research & Development, LLC | 10 months | 3 | EudraCT-2014-004587-38 |
| 2020 | Alzheimer's disease | Biogen GmbH | 9 days | 2 | EudraCT-2019-004368-22 |
| 2016 | Acute Infection | Vertex Inc. | 3 months | 1 | EudraCT-2014-004068-39 |
| 2021 | Vaccine COVID-19 | Bavarian Nordic A/S | 5 months | 163 | EudraCT-2021-001393-31 |
| 2015 | COPD | Pearl Therapeutics Ltd. | 4 months | 29 | EudraCT-2014-004712-10 |
| 2002 | Migraine | GlaxoSmithKline PLC | 4 months | 55 | n.d. |
| 2015 | Fibromyalgia | Daiichi Sankyo Development Ltd | 4 months | 5 | EudraCT-2013-005164-26 |
| 2002 | Restless Legs Syndrome | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 months | 35 | GDCT0062484 |
| 2015 | Addiction (Nicotine) | Philip Morris Products S.A. | 1 month | 13 | n.d. |
| 2002 | Restless Legs Syndrome | GlaxoSmithKline PLC | 3 months | 16 | GDCT50002921 |
| 2021 | COVID-19 | AiCuris Anti-Infective Cures GmbH | 6 months | 14 | EudraCT-2021-000167-69 |
| 2015 | COPD | AstraZeneca PLC | 4 months | 31 | EudraCT-2014-004715-37 |
| 2002 | Restless Legs Syndrome | GlaxoSmithKline PLC | 2 weeks | 9 | GDCT0309879 |
| 2022 | Menopausal Symptoms | Bayer Consumer Care AG | active | 6 | EudraCT-2020-004855-34 |
| 2015 | Depression | Alkermes PLC | 6 months | 60 | EudraCT-2014-000379-14 |
| 2002 | Schizophrenia | Janssen Research & Development, LLC, Johnson & Johnson | 6 months | 7 | n.d. |
| 2021 | Healthy Subjects | Heidelberg ImmunoTherapeutics GmbH | 5 months | 35 | n.d. |
| 2014 | COPD | GlaxoSmithKline PLC | 2 months | 15 | EudraCT-2014-000611-14 |
| 2002 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | 10 months | 13 | n.d. |
| 2020 | Herpes Labialis | Heidelberg ImmunoTherapeutics GmbH | active | 259 | EudraCT-2020-000926-24 |
| 2014 | COPD | GlaxoSmithKline PLC | 6 weeks | 12 | EudraCT-2011-005914-12 |
| 2002 | Generalized Anxiety Disorder | Orion Pharma GmbH | 5 months | 35 | n.d. |
| 2020 | Ulcerative Colitis | Novartis Pharma AG | active | 4 | EudraCT-2019-003113-34 |
| 2014 | COPD | Novartis Pharma GmbH | 2 months | 21 | EudraCT-2013-001477-25 |
| 2002 | Social Phobia | GlaxoSmithKline PLC | 3 months | 25 | n.d. |
| 2020 | Menopausal Symptoms | Sojournix, Inc | 3 months | 24 | EudraCT-2019-002281-12 |
| 2014 | Vaccine Clostridium difficile | Sanofi Pasteur SA | 11 months | 6 | EudraCT-2013-000775-32 |
| 2001 | Depression | Servier Laboratories UK Ltd | 3 months | 9 | n.d. |
| 2018 | Depression | Janssen Research & Development, LLC | 12 months | 40 | EudraCT-2015-005282-22 |
| 2014 | Binge Eating Disorder | Shire Development LLC | 1 month | 1 | EudraCT-2012-004457-88 |
| 2001 | Panic Disorder | Pfizer Inc. | 12 months | 49 | n.d. |
| 2019 | Common Cold | Enzymatika AB, analyze & realize GmbH | 4 months | 90 | n.d. |
| 2016 | Vaccine Influenza | Janssen Research & Development, LLC | 3 months | 1 | EudraCT-2014-004068-39 |
| 2013 | COPD | AstraZeneca PLC | 3 months | 20 | EudraCT-2013-000116-14 |
| 2002 | Restless Legs Syndrome | GlaxoSmithKline PLC | n.d. | 8 | GDCT0310475 |
| 2013 | Vaccine Herpes Zoster | GlaxoSmithKline PLC | 1 month | 16 | EudraCT-2015-000965-30 |
| 2000 | Depression | Boehringer Ingelheim Pharma GmbH & Co. KG | 12 months | 60 | n.d. |
| 2013 | Obstipation | Ferring B.V. | 6 months | 24 | EudraCT-2012-005588-28 |
| 2017 | Migraine | CoLucid Pharmaceuticals, Inc. | 2 months | 17 | EudraCT-2015-005689-40 |
| 2006 | Diabetic Neuropathy | UCB (Schwarz Pharma) | 4 months | 19 | EudraCT-2005-005788-27 |
| 2013 | COPD | GlaxoSmithKline PLC | 1 week | 2 | EudraCT-2011-001644-29 |
| 2017 | Insomnia | Eisai Inc. | 10 months | 93 | EudraCT-2015-004347-39 |
| 2009 | Alzheimer's disease | Eli Lilly and Company | n.d. | 10 | EudraCT-2008-002758-39 |
| 2013 | Binge Eating Disorder | Shire Pharmaceuticals Group Plc | 2 months | 2 | EudraCT-2012-003310-14 |
| 2017 | Irritable Bowel Syndrome | Dr. Willmar Schwabe GmbH & Co. KG | 9 months | 23 | EudraCT-2014-004702-14 |
| 2011 | Depression | Eli Lilly and Company | n.d. | 15 | EudraCT-2010-021215-16 |
| 2012 | Depression | H. Lundbeck A/S, Otsuka Pharmaceutical | 8 months | 19 | EudraCT-2012-001380-76 |
| 2017 | Depression | Janssen Research & Development, LLC | 11 months | 12 | EudraCT-2016-001929-14 |
| 2012 | Depression | Takeda Global Research & Development Centre (Europe) Ltd., H. Lundbeck A/S | n.d. | 19 | GDCT0064027 |
| 2012 | Depression | Merck Sharp & Dohme LLC | 10 months | 5 | EudraCT-2011-005200-15 |
| 2017 | Osteoarthritis | Astellas Pharma Inc. | 1 month | 22 | EudraCT-2014-004996-22 |
| 2012 | Depression | Shire Development LLC | 12 months | 44 | EudraCT-2011-003018-17 |
| 2017 | Prediabetes | Glycemicon AG | 15 months | 62 | n.d. |
| 2004 | Depression | Pfizer Inc. | n.d. | 19 | EudraCT-2004-000450-23 |
| 2012 | Addiction (Nicotine) | Pfizer, S.L.U. | 2 years | 371 | EudraCT-2010-022914-15 |
| 2017 | Vaccine Clostridium difficile | Pfizer Inc. | 17 months | 30 | EudraCT-2016-003866-14 |
| 2011 | Alzheimer's disease | Sanofi-Synthelabo | n.d. | 6 | n.d. |
| 2012 | COPD | AstraZeneca PLC | 6 months | 27 | EudraCT-2011-001524-38 |
| 2016 | Urinary Tract Infections | Repha GmbH Biologische Arzneimittel | 20 months | 23 | EudraCT-2013-004653-25 |
| 2012 | Depression | Shire Pharmaceutical Development Ltd | n.d. | 41 | EudraCT-2011-003006-25 |
| 2012 | Irritable Bowel Syndrome | Laves-Arzneimittel GmbH | 2 years | 72 | 2011-001743-78 |
| 2017 | Allergic Rhinitis | ALK-Abelló Arzneimittel GmbH | 1 month | 8 | EudraCT-2017-000971-97 |
| 2008 | Vaccine Influenza | GlaxoSmithKline PLC | 2 months | 38 | EudraCT-2008-000872-25 |
| 2011 | Alzheimer's disease | Avraham Pharmaceuticals Ltd. | 17 months | 32 | EudraCT-2011-004187-30 |
| 2017 | COPD | AstraZeneca PLC, Pearl Therapeutics Ltd. | 1 month | 18 | EudraCT-2016-000154-34 |
| 2017 | COPD | Verona Pharma PLC | 4 months | 17 | EudraCT-2016-005205-40 |
| 2022 | Borderline Personality Disorder | Oryzon | active | EudraCT-2020-003469-20 | |
| 2011 | Alzheimer's disease | Genentech Inc. | 4 months | 6 | EudraCT-2010-021926-37 |
| 2017 | Acute Infection | Medicago Inc. | 2 months | 92 | EudraCT-2017-001239-38 |
| 2011 | Restless Legs Syndrome | UCB Biosciences GmbH | 4 months | 47 | EudraCT-2011-000053-23 |
| 2018 | Alzheimer's disease | Eisai Co., Ltd. | 10 months | 17 | EudraCT-2016-003928-23 |
| 2004 | Depression | Eli Lilly and Company | 3 months | 56 | GDCT0060310 |
| 2011 | Venous insufficiency | OM PHARMA SA | 4 months | 9 | EudraCT-2009-013391-44 |
| 2018 | Insomnia | Idorsia Pharmaceuticals Ltd. | 13 months | 239 | EudraCT-2017-004642-20 |
| 2007 | Diabetic Neuropathy | Swedish Orphan Biovitrum AB | 2 months | 1 | EudraCT-2006-005967-25 |
| 2011 | Psychiatric diagnosis, others | Weleda AG | 9 months | 201 | EudraCT-2010-024189-23 |
| 2018 | Acute Infection | Medicago Inc. | 12 months | 61 | EudraCT-2018-001894-26 |
| 2011 | Diabetes Mellitus Type II | MetaCure (USA), Inc. | 10 months | 3 | EudraCT-2010-020945-28 |
| 2018 | Osteoarthritis | Regeneron Pharmaceuticals Inc. | 9 months | 35 | EudraCT-2017-001702-15 |
| 2011 | Depression | Takeda Pharmaceutical Company Ltd. | 5 months | 46 | EudraCT-2011-005298-22 |
| 2018 | Onychomycosis | Moberg Pharma AB | 9 months | 71 | EudraCT-2016-001204-39 |
| 2011 | COPD | GlaxoSmithKline PLC | 9 months | 21 | EudraCT-2010-021802-39 |
| 2018 | Insomnia | Janssen Research & Development, LLC | 4 months | 32 | EudraCT-2017-000980-33 |
| 2011 | Hypertension | Institut de Recherches Internationales Servier | 6 months | 5 | EudraCT-2010-020945-28 |
| 2018 | Premenstrual Syndrome | Asarina Pharma AB | 17 months | 91 | EudraCT-2017-000822-37 |
| 2011 | Attention Deficit Hyperactive Disorder (adults) | Novartis Pharmaceuticals | 4 months | 70 | EudraCT-2011-004668-31 |
| 2018 | Uterine Fibroid | Bayer AG | 10 months | 11 | EudraCT-2016-002855-48 |
| 2011 | Depression | AstraZeneca PLC | 5 months | 18 | EudraCT-2010-019925-33 |
| 2016 | Onychomycosis | Polichem S.A. | 4 months | 59 | EudraCT-2015-000561-31 |
| 2011 | Stress Disorder | Dr. Willmar Schwabe GmbH & Co. KG | 4 months | 31 | EudraCT-2010-022114-12 |
| 2011 | Diabetes Mellitus Type II | Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company | 15 months | 18 | EudraCT-2010-021375-92 |
| 2015 | COPD | Novartis Pharma Services AG | 4 months | 15 | EudraCT-2013-003127-11 |
| 2014 | Diabetes Mellitus Type II | Hanmi Pharm.Co.,Ltd. | 5 months | 1 | EudraCT-2013-004250-13 |
| 2010 | Common Cold | Enzymatika AB, analyze & realize GmbH, Leiber GmbH | 1 month | 60 | n.d. |
| 2013 | Depression | Forest Research Institute | 12 months | 25 | EudraCT-2012-001950-25 |
| 2012 | COPD | Allergan PLC, Almirall, S.A., AstraZeneca PLC | 6 months | 27 | EudraCT-2011-001524-38 |
| 2011 | COPD | GlaxoSmithKline PLC | 6 months | 20 | EudraCT-2010-021802-39 |
| 2010 | Vaccine Influenza | Sanofi Pasteur SA, Merck Sharp & Dohme LLC | 2 months | 108 | EudraCT-2010-021068-13 |
| 2008 | Generalized Anxiety Disorder | H. Lundbeck A/S, Takeda Global Research & Development Centre (Europe) Ltd. | 3 months | 10 | EudraCT-2008-001766-90 |
| 2008 | Depression | Takeda Global Research & Development Centre (Europe) Ltd. | 8 months | 28 | EudraCT-2008-001580-11 |
| 2008 | Diabetes Mellitus Type II | Eli Lilly and Company | 4 months | 4 | EudraCT-2008-004207-63 |
| 2010 | Obstipation | Shire Pharmaceuticals Group Plc, Shire-Movetis NV | 32 months | 16 | EudraCT-2009-015719-42 |
| 2006 | Metrorrhagia | Bayer Schering Pharma AG | 6 months | 11 | EudraCT-2005-004340-32 |
| 2010 | Depression | Sanofi-Aventis Recherche & Développement | 7 months | 33 | EudraCT-2009-010339-42 |
| 2006 | Parkinson Disease | Axxonis Pharma AG | 2 months | 1 | EudraCT-2006-003732-30 |
| 2006 | Restless Legs Syndrome | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 months | 4 | EudraCT-2005-005225-54 |
| 2003 | Diabetes Mellitus Type II | GlaxoSmithKline PLC | 8 months | 5 | n.d. |
| 2010 | Depression | GlaxoSmithKline PLC | 4 months | 22 | EudraCT-2009-010339-42 |
| 2017 | Psoriasis | Novartis Pharma Services AG | 4 months | 4 | EudraCT-2015-005170-38 |
| 2009 | Addiction (Alcohol) | H. Lundbeck A/S | 11 months | 121 | EudraCT-2007-002315-92 |
| 2017 | Hyperlipidemia | ESPERION Therapeutics Inc., AstraZeneca PLC | 2 months | 4 | EudraCT-2016-004115-12 |
| 2015 | Depression | Alkermes PLC | 5 months | 14 | EudraCT-2014-000380-41 |
| 2017 | Depression | Janssen Research & Development, LLC | 3 months | 29 | EudraCT-2015-005282-22 |
| 2009 | Depression | H. Lundbeck A/S | 2 months | 6 | EudraCT-2007-001871-13 |
| 2018 | Insomnia | Idorsia Pharmaceuticals Ltd. | 13 months | 16 | EudraCT-2017-004644-38 |
| 2009 | Alzheimer's disease | Institut de Recherches Internationales Servier | 7 months | 7 | n.d. |
| 2018 | Depression | Janssen-Cilag GmbH | 3 months | 32 | EudraCT- 2017-002633-28 |
| 2009 | Diabetes Mellitus Type II | Novartis Pharma Services AG | 7 months | 6 | EudraCT-2008-002758-39 |
| 2019 | Depression | Janssen Research & Development, LLC | 5 months | 14 | EudraCT-2015-005282-23 |
| 2009 | Restless Legs Syndrome | Pfizer Inc. | 6 months | 16 | EudraCT-2008-005889-32 |
| 2019 | Irritable Bowel Syndrome | Cosmo Pharmaceuticals NV | 13 months | 62 | EudraCT-2016-004977-42 |
| 2009 | Diabetes Mellitus Type II | Boehringer Ingelheim Pharma GmbH & Co. KG | 8 months | 2 | EudraCT-2008-008296-33 |
| 2019 | Cardiovascular Diesase | Novartis Pharmaceuticals | 8 months | 35 | EudraCT-2018-003786-34 |
| 2009 | Osteoarthritis | Eli Lilly and Company | 4 months | 12 | EudraCT-2009-010008-27 |
| 2018 | Diabetes Mellitus Type II | Novo Nordisk A/S | 4 months | 4 | EudraCT-2017-003219-20 |
| 2019 | Statin Intolerance | ESPERION Therapeutics Inc. | 9 days | 3 | EudraCT-2016-003485-11 |
| 2019 | Obesity | Novo Nordisk A/S | 21 months | 34 | Eudra CT-2017-003380-35 |
| 2009 | Depression | Takeda Global Research & Development Centre (Europe) Ltd. | 1 month | 49 | EudraCT-2008-001581-91 |
| 2019 | Insomnia | Idorsia Pharmaceuticals Ltd. | 4 months | 7 | EudraCT-2017-004644-38 |
| 2009 | Insomnia | GlaxoSmithKline PLC | 2 months | 29 | EudraCT-2008-006345-72 |
| 2019 | Acute Infection | Sanofi Pasteur SA | 6 weeks | 99 | EudraCT-2019-000655-14 |
| 2019 | Alopecia Areata | Pfizer Inc. | 4 months | 3 | EudraCT-2018-001714-14 |
| 2008 | Vaccine Herpes Zoster | Merck Sharp & Dohme LLC | 8 months | 844 | EudraCT-2007-004020-20 |
| 2019 | Atopic Dermatitis | Pfizer Inc. | 3 months | 3 | EudraCT-2018-003050-24 |
| 2008 | Hypertension | Novartis Pharma Services AG | 4 months | 18 | EudraCT-2006-006068-44 |
| 2019 | Hyperhidrosis | Dr. August Wolff GmbH & Co. KG Arzneimittel | 5 months | 108 | EudraCT-2017-004534-29 |
| 2019 | Herpes Genitalis | Heidelberg ImmunoTherapeutics GmbH | 11 months | 108 | EudraCT-2019-000880-26 |
| 2008 | Alzheimer's disease | Eli Lilly and Company | 1 month | 3 | EudraCT-2008-002758-39 |
| 2019 | Psoriasis | Pfizer Inc. | 4 weeks | 4 | EudraCT-2018-003051-38 |
| 2019 | Irritable Bowel Syndrome | Repha GmbH Biologische Arzneimittel | 18 months | 4 | EudraCT-2019-000245-12 |
| 2019 | Irritable Bowel Syndrome | SymbioPharm GmbH | active | 15 | EudraCT-2018-004626-28 |
| 2008 | Irritable Bowel Syndrome | Menarini Group | 3 months | 24 | EudraCT-2008-000214-71 |
| 2019 | Depression | Allergan Inc | 8 months | 8 | EudraCT-2018-002782-19 |
| 2008 | Overactive Bladder (OAB) | Pfizer Inc. | 4 months | 18 | EudraCT-2007-006451-39 |
| 2020 | Vaccine Tetanus-Diphtheria-Pertussis | Vakzine Projekt Management GmbH | 8 weeks | 506 | EudraCT-2019-002706-46 |
| 2008 | Migraine | Merck Sharp & Dohme LLC | 3 months | 55 | EudraCT-2007-002667-28 |
| 2008 | Low Back Pain | Eli Lilly and Company | 6 months | 12 | EudraCT-2008-002248-40 |
| 2008 | Depression | Sanofi-Aventis Recherche & Développement | 6 months | 29 | EudraCT-2007-003863-31 |
| 2008 | Diabetes Mellitus Type II | Merck Sharp & Dohme LLC | 1 month | 4 | EudraCT-2007-000145-35 |
| 2020 | Depression | Janssen-Cilag International NV | 4 Wochen | 3 | EudraCT-2019-002992-33 |
| 2010 | Depression | H. Lundbeck A/S, Takeda Global Research & Development Centre (Europe) Ltd. | 9 months | 43 | EudraCT-2008-001580-11 |
| 2008 | Female Sexual Dysfunction | Bayer Schering Pharma AG | 4 months | 13 | Eudract-2006-004397-27 |
| 2020 | Vasomotor Symptoms | Sojournix Inc. | 3 months | 24 | EudraCT-2019-002281-12 |
| 2008 | Hyperlipidemia | Merck Sharp & Dohme LLC | 2 months | 33 | EudraCT-2011-001007-12 |
| 2008 | Hypertension | Takeda Pharmaceutical Company Ltd. | 2 months | 10 | EudraCT-2007-002583-10 |
| 2007 | Female Sexual Dysfunction | Boehringer Ingelheim Pharma GmbH & Co. KG | 11 months | 60 | EudraCT-2007-000032-68 |
| 2020 | Vaccine Tuberculosis | Vakzine Projekt Management GmbH | 6 months | 195 | EudraCT-2020-001675-33 |
| 2007 | Depression | GlaxoSmithKline PLC | 10 months | 36 | EudraCT-2005-003400-11 |
| 2020 | Alopecia Areata | Pfizer Inc. | 3 months | 4 | EudraCT-2019-001084-71 |
| 2007 | Depression | Sanofi-Aventis Recherche & Développement | 10 months | 36 | EudraCT-2004-002328-16 |
| 2007 | Depression | Institut de Recherches Internationales Servier | 10 months | 16 | EudraCT-2006-004716-48 |
| 2007 | Insomnia | Sanofi-Aventis Recherche & Développement | 12 months | 14 | EudraCT-2006-004942-18 |
| 2018 | Prediabetes | Novo Nordisk A/S | 7 months | 4 | EudraCT-2017-003219-20 |
| 2016 | Fibromyalgia | Daiichi Sankyo Development Ltd | 6 months | 28 | EudraCT-2013-005161-40 |
| 2007 | Polyneuropathy | Grünenthal GmbH | 4 months | 8 | EudraCT-2006-003132-29 |
| 2016 | Contraception | Mithra Pharmaceuticals, Estetra SPRL | 4 months | 21 | EudraCT-2015-003150-40 |
| 2007 | Polyneuropathy | Grünenthal GmbH | 4 months | 8 | EudraCT-2006-003132-29 |
| 2007 | Hypertension | Daiichi Sankyo Europe GmbH | 19 months | 19 | EudraCT-2006-003877-28 |
| 2015 | Osteoarthritis | Pro Bono Bio International Trading Ltd. | 4 months | 56 | GDCT0269718 |
| 2007 | Restless Legs Syndrome | Boehringer Ingelheim Pharma GmbH & Co. KG | 4 months | 34 | EudraCT-2006-006431-42 |
| 2014 | Obesity | Hanmi Pharm.Co.,Ltd. | n.d. | 52 | EudraCT-2013-004251-21 |
| 2007 | Migraine | Merck Sharp & Dohme GmbH | 5 months | 35 | EudraCT-2006-006187-35 |
| 2014 | Binge Eating Disorder | Shire Development LLC | 1 month | 1 | EudraCT-2012-003313-34 |
| 2007 | Generalized Anxiety Disorder | Sanofi-Aventis Recherche & Développement | 6 months | 16 | EudraCT-2006-002253-71 |
| 2007 | Depression | Pierre Fabre Médicament | 5 months | 11 | EudraCT-2006-002404-34 |
| 2013 | Vaccine Herpes Zoster, Vaccine Influenza | GlaxoSmithKline PLC | n.d. | 16 | EudraCT-2013-000372-15 |
| 2006 | Social Phobia | GlaxoSmithKline PLC | 5 months | 16 | EudraCT-2006-003597-10 |
| 2010 | Diabetes Mellitus Type II | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 months | 10 | EudraCT-2009-013157-15 |
| 2010 | Restless Legs Syndrome | Mundipharma GmbH | n.d. | 21 | EudraCT-2009-011107-23 |